Search

Your search keyword '"Krämer, Alwin"' showing total 410 results
Start Over Author "Krämer, Alwin" Publication Type Academic Journals
410 results on '"Krämer, Alwin"'

3. High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders

Author

Köhrer, Sebastian, Dittrich, Tobias, Schorb, Martin, Weinhold, Niels, Haberbosch, Isabella, Börmel, Mandy, Pajor, Gabor, Goldschmidt, Hartmut, Müller-Tidow, Carsten, Raab, Marc S., John, Lukas, Seckinger, Anja, Brobeil, Alexander, Dreger, Peter, Tornóczky, Tamás, Pajor, László, Hegenbart, Ute, Schönland, Stefan O., Schwab, Yannick, and Krämer, Alwin

Published
2023
Full Text
View/download PDF

4. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study

Author

Krämer, Alwin, Bochtler, Tilmann, Pauli, Chantal, Shiu, Kai-Keen, Cook, Natalie, de Menezes, Juliana Janoski, Pazo-Cid, Roberto A, Losa, Ferran, Robbrecht, Debbie GJ, Tomášek, Jiří, Arslan, Cagatay, Özgüroğlu, Mustafa, Stahl, Michael, Bigot, Frédéric, Kim, Sun Young, Naito, Yoichi, Italiano, Antoine, Chalabi, Nasséra, Durán-Pacheco, Gonzalo, Michaud, Chantal, Scarato, Jeremy, Thomas, Marlene, Ross, Jeffrey S, Moch, Holger, and Mileshkin, Linda

Published
2024
Full Text
View/download PDF

5. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Author

Pouyiourou, Maria, Kraft, Bianca N., Wohlfromm, Timothy, Stahl, Michael, Kubuschok, Boris, Löffler, Harald, Hacker, Ulrich T., Hübner, Gerdt, Weiss, Lena, Bitzer, Michael, Ernst, Thomas, Schütt, Philipp, Hielscher, Thomas, Delorme, Stefan, Kirchner, Martina, Kazdal, Daniel, Ball, Markus, Kluck, Klaus, Stenzinger, Albrecht, Bochtler, Tilmann, and Krämer, Alwin

Published
2023
Full Text
View/download PDF

9. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

Author

Niederwieser, Dietger, Lang, Thomas, Krahl, Rainer, Heinicke, Thomas, Maschmeyer, Georg, Al-Ali, Haifa Kathrin, Schwind, Sebastian, Jentzsch, Madlen, Cross, Michael, Kahl, Christoph, Wolf, Hans-Heinrich, Sayer, Herbert, Schulze, Antje, Dreger, Peter, Hegenbart, Ute, Krämer, Alwin, Junghanss, Christian, Mügge, Lars-Olof, Hähling, Detlev, Hirt, Carsten, Späth, Christian, Peter, Norma, Opitz, Bernhard, Florschütz, Axel, Reifenrath, Kolja, Zojer, Niklas, Scholl, Sebastian, Pönisch, Wolfram, Heyn, Simone, Vucinic, Vladan, Hochhaus, Andreas, Aul, Carlo, Giagounidis, Aristoteles, Balleisen, Leopold, Oldenkott, Bernd, Staib, Peter, Kiehl, Michael, Schütte, Wolfgang, Naumann, Ralph, Eimermacher, Hartmut, Dörken, Bernd, Sauerland, Cristina, Lengfelder, Eva, Hiddemann, Wolfgang, Wörmann, Bernhard, Müller-Tidow, Carsten, Serve, Hubert, Schliemann, Christoph, Hehlmann, Rüdiger, Berdel, Wolfgang E., Pfirrmann, Markus, Krug, Utz, and Hoffmann, Verena S.

Published
2023
Full Text
View/download PDF

11. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41

Author

Homan, Claire C., Drazer, Michael W., Yu, Kai, Lawrence, David M., Feng, Jinghua, Arriola-Martinez, Luis, Pozsgai, Matthew J., McNeely, Kelsey E., Ha, Thuong, Venugopal, Parvathy, Arts, Peer, King-Smith, Sarah L., Cheah, Jesse, Armstrong, Mark, Wang, Paul, Bödör, Csaba, Cantor, Alan B., Cazzola, Mario, Degelman, Erin, DiNardo, Courtney D., Duployez, Nicolas, Favier, Remi, Fröhling, Stefan, Rio-Machin, Ana, Klco, Jeffery M., Krämer, Alwin, Kurokawa, Mineo, Lee, Joanne, Malcovati, Luca, Morgan, Neil V., Natsoulis, Georges, Owen, Carolyn, Patel, Keyur P., Preudhomme, Claude, Raslova, Hana, Rienhoff, Hugh, Ripperger, Tim, Schulte, Rachael, Tawana, Kiran, Velloso, Elvira, Yan, Benedict, Kim, Erika, Sood, Raman, Hsu, Amy P., Holland, Steven M., Phillips, Kerry, Poplawski, Nicola K., Babic, Milena, Wei, Andrew H., Forsyth, Cecily, Mar Fan, Helen, Lewis, Ian D., Cooney, Julian, Susman, Rachel, Fox, Lucy C., Blombery, Piers, Singhal, Deepak, Hiwase, Devendra, Phipson, Belinda, Schreiber, Andreas W., Hahn, Christopher N., Scott, Hamish S., Liu, Paul, Godley, Lucy A., and Brown, Anna L.

Published
2023
Full Text
View/download PDF

13. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Author

Kunadt, Desiree, Stasik, Sebastian, Metzeler, Klaus H., Röllig, Christoph, Schliemann, Christoph, Greif, Philipp A., Spiekermann, Karsten, Rothenberg-Thurley, Maja, Krug, Utz, Braess, Jan, Krämer, Alwin, Hochhaus, Andreas, Scholl, Sebastian, Hilgendorf, Inken, Brümmendorf, Tim H., Jost, Edgar, Steffen, Björn, Bug, Gesine, Einsele, Hermann, Görlich, Dennis, Sauerland, Cristina, Schäfer-Eckart, Kerstin, Krause, Stefan W., Hänel, Mathias, Hanoun, Maher, Kaufmann, Martin, Wörmann, Bernhard, Kramer, Michael, Sockel, Katja, Egger-Heidrich, Katharina, Herold, Tobias, Ehninger, Gerhard, Burchert, Andreas, Platzbecker, Uwe, Berdel, Wolfgang E., Müller-Tidow, Carsten, Hiddemann, Wolfgang, Serve, Hubert, Stelljes, Matthias, Baldus, Claudia D., Neubauer, Andreas, Schetelig, Johannes, Thiede, Christian, Bornhäuser, Martin, Middeke, Jan M., and Stölzel, Friedrich

Published
2022
Full Text
View/download PDF

14. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Author

Eckardt, Jan-Niklas, Stölzel, Friedrich, Kunadt, Desiree, Röllig, Christoph, Stasik, Sebastian, Wagenführ, Lisa, Jöhrens, Korinna, Kuithan, Friederike, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Herbst, Regina, Hänel, Mathias, Hanoun, Maher, Kaiser, Ulrich, Kaufmann, Martin, Rácil, Zdenek, Mayer, Jiri, Kroschinsky, Frank, Berdel, Wolfgang E., Ehninger, Gerhard, Serve, Hubert, Müller-Tidow, Carsten, Platzbecker, Uwe, Baldus, Claudia D., Schetelig, Johannes, Bornhäuser, Martin, Thiede, Christian, and Middeke, Jan Moritz

Published
2022
Full Text
View/download PDF

16. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

Author

Middeke, Jan M., Metzeler, Klaus H., Röllig, Christoph, Krämer, Michael, Eckardt, Jan-Niklas, Stasik, Sebastian, Greif, Philipp A., Spiekermann, Karsten, Rothenberg-Thurley, Maja, Krug, Utz, Braess, Jan, Krämer, Alwin, Hochhaus, Andreas, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Görlich, Dennis, Sauerland, Cristina, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Kaufmann, Martin, Kunadt, Desiree, Wörmann, Bernhard, Sockel, Katja, von Bonin, Malte, Herold, Tobias, Müller-Tidow, Carsten, Platzbecker, Uwe, Berdel, Wolfgang E., Serve, Hubert, Baldus, Claudia D., Ehninger, Gerhard, Schetelig, Johannes, Hiddemann, Wolfgang, Bornhäuser, Martin, Stölzel, Friedrich, and Thiede, Christian

Published
2022
Full Text
View/download PDF

17. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

Author

Taube, Franziska, Georgi, Julia Annabell, Kramer, Michael, Stasik, Sebastian, Middeke, Jan Moritz, Röllig, Christoph, Krug, Utz, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Brümmendorf, Tim H., Naumann, Ralph, Petzold, Andreas, Mulet-Lazaro, Roger, Valk, Peter J.M., Steffen, Björn, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Hänel, Mathias, Noppeney, Richard, Kaiser, Ulrich, Baldus, Claudia D., Kaufmann, Martin, Herold, Sylvia, Stölzel, Friedrich, Sockel, Katja, von Bonin, Malte, Müller-Tidow, Carsten, Platzbecker, Uwe, Berdel, Wolfgang E., Serve, Hubert, Ehninger, Gerhard, Bornhäuser, Martin, Schetelig, Johannes, and Thiede, Christian

Published
2022
Full Text
View/download PDF

18. Prediction of acute myeloid leukaemia risk in healthy individuals.

Author

Abelson, Sagi, Collord, Grace, Ng, Stanley WK, Weissbrod, Omer, Mendelson Cohen, Netta, Niemeyer, Elisabeth, Barda, Noam, Zuzarte, Philip C, Heisler, Lawrence, Sundaravadanam, Yogi, Luben, Robert, Hayat, Shabina, Wang, Ting Ting, Zhao, Zhen, Cirlan, Iulia, Pugh, Trevor J, Soave, David, Ng, Karen, Latimer, Calli, Hardy, Claire, Raine, Keiran, Jones, David, Hoult, Diana, Britten, Abigail, McPherson, John D, Johansson, Mattias, Mbabaali, Faridah, Eagles, Jenna, Miller, Jessica K, Pasternack, Danielle, Timms, Lee, Krzyzanowski, Paul, Awadalla, Philip, Costa, Rui, Segal, Eran, Bratman, Scott V, Beer, Philip, Behjati, Sam, Martincorena, Inigo, Wang, Jean CY, Bowles, Kristian M, Quirós, J Ramón, Karakatsani, Anna, La Vecchia, Carlo, Trichopoulou, Antonia, Salamanca-Fernández, Elena, Huerta, José M, Barricarte, Aurelio, Travis, Ruth C, Tumino, Rosario, Masala, Giovanna, Boeing, Heiner, Panico, Salvatore, Kaaks, Rudolf, Krämer, Alwin, Sieri, Sabina, Riboli, Elio, Vineis, Paolo, Foll, Matthieu, McKay, James, Polidoro, Silvia, Sala, Núria, Khaw, Kay-Tee, Vermeulen, Roel, Campbell, Peter J, Papaemmanuil, Elli, Minden, Mark D, Tanay, Amos, Balicer, Ran D, Wareham, Nicholas J, Gerstung, Moritz, Dick, John E, Brennan, Paul, Vassiliou, George S, and Shlush, Liran I

Subjects
Humans, Disease Progression, Genetic Predisposition to Disease, Prevalence, Risk Assessment, Age Factors, Mutagenesis, Mutation, Models, Genetic, Adult, Aged, Middle Aged, Health, Female, Male, Leukemia, Myeloid, Acute, Electronic Health Records, Models, Genetic, Leukemia, Myeloid, Acute, General Science & Technology
Abstract

The incidence of acute myeloid leukaemia (AML) increases with age and mortality exceeds 90% when diagnosed after age 65. Most cases arise without any detectable early symptoms and patients usually present with the acute complications of bone marrow failure1. The onset of such de novo AML cases is typically preceded by the accumulation of somatic mutations in preleukaemic haematopoietic stem and progenitor cells (HSPCs) that undergo clonal expansion2,3. However, recurrent AML mutations also accumulate in HSPCs during ageing of healthy individuals who do not develop AML, a phenomenon referred to as age-related clonal haematopoiesis (ARCH)4-8. Here we use deep sequencing to analyse genes that are recurrently mutated in AML to distinguish between individuals who have a high risk of developing AML and those with benign ARCH. We analysed peripheral blood cells from 95 individuals that were obtained on average 6.3 years before AML diagnosis (pre-AML group), together with 414 unselected age- and gender-matched individuals (control group). Pre-AML cases were distinct from controls and had more mutations per sample, higher variant allele frequencies, indicating greater clonal expansion, and showed enrichment of mutations in specific genes. Genetic parameters were used to derive a model that accurately predicted AML-free survival; this model was validated in an independent cohort of 29 pre-AML cases and 262 controls. Because AML is rare, we also developed an AML predictive model using a large electronic health record database that identified individuals at greater risk. Collectively our findings provide proof-of-concept that it is possible to discriminate ARCH from pre-AML many years before malignant transformation. This could in future enable earlier detection and monitoring, and may help to inform intervention.

Published
2018

19. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

Author

Cortes, Jorge, Perl, Alexander E, Döhner, Hartmut, Kantarjian, Hagop, Martinelli, Giovanni, Kovacsovics, Tibor, Rousselot, Philippe, Steffen, Björn, Dombret, Hervé, Estey, Elihu, Strickland, Stephen, Altman, Jessica K, Baldus, Claudia D, Burnett, Alan, Krämer, Alwin, Russell, Nigel, Shah, Neil P, Smith, Catherine C, Wang, Eunice S, Ifrah, Norbert, Gammon, Guy, Trone, Denise, Lazzaretto, Deborah, and Levis, Mark

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Hematology, Cancer, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Administration, Oral, Adult, Aged, Benzothiazoles, Canada, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Europe, Female, Humans, Internationality, Leukemia, Myeloid, Acute, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Recurrence, Local, Phenylurea Compounds, Prognosis, Survival Rate, Treatment Outcome, United States, Young Adult, fms-Like Tyrosine Kinase 3, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundOld age and FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations in patients with acute myeloid leukaemia are associated with early relapse and poor survival. Quizartinib is an oral, highly potent, and selective next-generation FLT3 inhibitor with clinical antileukaemic activity in relapsed or refractory acute myeloid leukaemia. We aimed to assess the efficacy and safety of single-agent quizartinib in patients with relapsed or refractory acute myeloid leukaemia.MethodsWe did an open-label, multicentre, single-arm, phase 2 trial at 76 hospitals and cancer centres in the USA, Europe, and Canada. We enrolled patients with morphologically documented primary acute myeloid leukaemia or acute myeloid leukaemia secondary to myelodysplastic syndromes and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 into two predefined, independent cohorts: patients who were aged 60 years or older with relapsed or refractory acute myeloid leukaemia within 1 year after first-line therapy (cohort 1), and those who were 18 years or older with relapsed or refractory disease following salvage chemotherapy or haemopoietic stem cell transplantation (cohort 2). Patients with an FLT3-ITD allelic frequency of more than 10% were considered as FLT3-ITD positive, whereas all other patients were considered as FLT3-ITD negative. Patients received quizartinib once daily as an oral solution; the initial 17 patients received 200 mg per day but the QTcF interval was prolonged for more than 60 ms above baseline in some of these patients. Subsequently, doses were amended for all patients to 135 mg per day for men and 90 mg per day for women. The co-primary endpoints were the proportion of patients who achieved a composite complete remission (defined as complete remission + complete remission with incomplete platelet recovery + complete remission with incomplete haematological recovery) and the proportion of patients who achieved a complete remission. Efficacy and safety analyses included all patients who received at least one dose of quizartinib (ie, the intention-to-treat population). Patients with a locally assessed post-treatment bone marrow aspirate or biopsy were included in efficacy analyses by response; all other patients were considered to have an unknown response. This study is registered with ClinicalTrials.gov, number NCT00989261, and with the European Clinical Trials Database, EudraCT 2009-013093-41, and is completed.FindingsBetween Nov 19, 2009, and Oct 31, 2011, a total of 333 patients were enrolled (157 in cohort 1 and 176 in cohort 2). In cohort 1, 63 (56%) of 112 FLT3-ITD-positive patients and 16 (36%) of 44 FLT3-ITD-negative patients achieved composite complete remission, with three (3%) FLT3-ITD-positive patients and two (5%) FLT3-ITD-negative patients achieving complete remission. In cohort 2, 62 (46%) of 136 FLT3-ITD-positive patients achieved composite complete remission with five (4%) achieving complete remission, whereas 12 (30%) of 40 FLT3-ITD-negative patients achieved composite complete remission with one (3%) achieving complete remission. Across both cohorts (ie, the intention-to-treat population of 333 patients), grade 3 or worse treatment-related treatment-emergent adverse events in 5% or more of patients were febrile neutropenia (76 [23%] of 333), anaemia (75 [23%]), thrombocytopenia (39 [12%]), QT interval corrected using Fridericia's formula (QTcF) prolongation (33 [10%]), neutropenia (31 [9%]), leucopenia (22 [7%]), decreased platelet count (20 [6%]), and pneumonia (17 [5%]). Serious adverse events occurring in 5% or more of patients were febrile neutropenia (126 [38%] of 333; 76 treatment related), acute myeloid leukaemia progression (73 [22%]), pneumonia (40 [12%]; 14 treatment related), QTcF prolongation (33 [10%]; 32 treatment related), sepsis (25 [8%]; eight treatment related), and pyrexia (18 [5%]; nine treatment related). Notable serious adverse events occurring in less than 5% of patients were torsades de pointes (one [

Published
2018

20. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

Author

Stasik, Sebastian, Eckardt, Jan-Niklas, Kramer, Michael, Röllig, Christoph, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan, Herbst, Regina, Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Baldus, Claudia D., Kaufmann, Martin, Rácil, Zdenek, Platzbecker, Uwe, Berdel, Wolfgang E., Mayer, Jiri, Serve, Hubert, Müller-Tidow, Carsten, Ehninger, Gerhard, Bornhäuser, Martin, Schetelig, Johannes, Middeke, Jan M., and Thiede, Christian

Published
2021
Full Text
View/download PDF

21. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial

Author

Ganguly, Siddhartha, Cortes, Jorge E., Krämer, Alwin, Levis, Mark J., Martinelli, Giovanni, Perl, Alexander E., Russell, Nigel H., Arunachalam, Meena, Santos, Cedric Dos, Gammon, Guy, Lesegretain, Arnaud, Mires, Derek E., Pham, Hoang, Wang, Yibin, and Khaled, Samer K.

Published
2021
Full Text
View/download PDF

23. Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

Author

Heuser, Michael, Palmisiano, Neil, Mantzaris, Ioannis, Mims, Alice, DiNardo, Courtney, Silverman, Lewis R., Wang, Eunice S., Fiedler, Walter, Baldus, Claudia, Schwind, Sebastian, Pardee, Timothy, Perl, Alexander E., Cai, Charles, Kaulfuss, Stefan, Lagkadinou, Eleni, Rentzsch, Christine, Wagner, Markus, Wilkinson, Gary, Wu, Bingyan, Jeffers, Michael, Genvresse, Isabelle, and Krämer, Alwin

Published
2020
Full Text
View/download PDF

24. The clinical mutatome of core binding factor leukemia

Author

Opatz, Sabrina, Bamopoulos, Stefanos A., Metzeler, Klaus H., Herold, Tobias, Ksienzyk, Bianka, Bräundl, Kathrin, Tschuri, Sebastian, Vosberg, Sebastian, Konstandin, Nikola P., Wang, Christine, Hartmann, Luise, Graf, Alexander, Krebs, Stefan, Blum, Helmut, Schneider, Stephanie, Thiede, Christian, Middeke, Jan Moritz, Stölzel, Friedrich, Röllig, Christoph, Schetelig, Johannes, Ehninger, Gerhard, Krämer, Alwin, Braess, Jan, Görlich, Dennis, Sauerland, Maria Cristina, Berdel, Wolfgang E., Wörmann, Bernhard J., Hiddemann, Wolfgang, Spiekermann, Karsten, Bohlander, Stefan K., and Greif, Philipp A.

Published
2020
Full Text
View/download PDF

26. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Author

Cortes, Jorge E, Khaled, Samer, Martinelli, Giovanni, Perl, Alexander E, Ganguly, Siddhartha, Russell, Nigel, Krämer, Alwin, Dombret, Hervé, Hogge, Donna, Jonas, Brian A, Leung, Anskar Yu-Hung, Mehta, Priyanka, Montesinos, Pau, Radsak, Markus, Sica, Simona, Arunachalam, Meena, Holmes, Melissa, Kobayashi, Ken, Namuyinga, Ruth, Ge, Nanxiang, Yver, Antoine, Zhang, Yufen, and Levis, Mark J

Published
2019
Full Text
View/download PDF

29. Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia

Author

Bochtler, Tilmann, Granzow, Martin, Stölzel, Friedrich, Kunz, Christina, Mohr, Brigitte, Kartal-Kaess, Mutlu, Hinderhofer, Katrin, Heilig, Christoph E., Kramer, Michael, Thiede, Christian, Endris, Volker, Kirchner, Martina, Stenzinger, Albrecht, Benner, Axel, Bornhäuser, Martin, Ehninger, Gerhard, Ho, Anthony D., Jauch, Anna, and Krämer, Alwin

Published
2017
Full Text
View/download PDF

32. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Author

Röllig, Christoph, Serve, Hubert, Hüttmann, Andreas, Noppeney, Richard, Müller-Tidow, Carsten, Krug, Utz, Baldus, Claudia D, Brandts, Christian H, Kunzmann, Volker, Einsele, Hermann, Krämer, Alwin, Schäfer-Eckart, Kerstin, Neubauer, Andreas, Burchert, Andreas, Giagounidis, Aristoteles, Krause, Stefan W, Mackensen, Andreas, Aulitzky, Walter, Herbst, Regina, Hänel, Mathias, Kiani, Alexander, Frickhofen, Norbert, Kullmer, Johannes, Kaiser, Ulrich, Link, Hartmut, Geer, Thomas, Reichle, Albert, Junghanß, Christian, Repp, Roland, Heits, Frank, Dürk, Heinz, Hase, Jana, Klut, Ina-Maria, Illmer, Thomas, Bornhäuser, Martin, Schaich, Markus, Parmentier, Stefani, Görner, Martin, Thiede, Christian, von Bonin, Malte, Schetelig, Johannes, Kramer, Michael, Berdel, Wolfgang E, and Ehninger, Gerhard

Published
2015
Full Text
View/download PDF

36. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

Author

Döhner, Hartmut, Lübbert, Michael, Fiedler, Walter, Fouillard, Loic, Haaland, Alf, Brandwein, Joseph M., Lepretre, Stephane, Reman, Oumedaly, Turlure, Pascal, Ottmann, Oliver G., Müller-Tidow, Carsten, Krämer, Alwin, Raffoux, Emmanuel, Döhner, Konstanze, Schlenk, Richard F., Voss, Florian, Taube, Tillmann, Fritsch, Holger, and Maertens, Johan

Published
2014
Full Text
View/download PDF

39. Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41

Author

Brown, Anna L., Homan, Claire, Drazer, Michael W., Yu, Kai, Lawrence, David, Feng, Jinghua, Arriola-Martinez, Luis, Pozsgai, Matthew, McNeely, Kelsey, Ha, Thuong, Venugopal, Parvathy, Arts, Peer, King-Smith, Sarah, Cheah, Jesse JC, Armstrong, Mark, Bödör, Csaba, Wang, Paul, Cantor, Alan B., Cazzola, Mario, Degelman, Erin, DiNardo, Courtney D., Duployez, Nicolas, Favier, Remi, Fröhling, Stefan, Rio-Machin, Ana, Klco, Jeffery M., Krämer, Alwin, Kurokawa, Mineo, Lee, Joanne, Malcovati, Luca, Morgan, Neil V, Natsoulis, Georges, Owen, Carolyn, Patel, Keyur P., Preudhomme, Claude, Raslova, Hana, Rienhoff, Hugh Young, Jr., Ripperger, Tim, Schulte, Rachael, Tawana, Kiran, Velloso, Elvira Deolinda Rodrigues Pereira, Yan, Benedict, Sood, Raman, Hsu, Amy, Holland, Steven M., Phillips, Kerry, Poplawski, Nicola, Babic, Milena, Kwon Kim, Erika M, Wei, Andrew H., Forsyth, Cecily, Mar Fan, Helen, Lewis, Ian D, Cooney, Julian, Susman, Rachel, Fox, Lucy C, Blombery, Piers, Singhal, Deepak, Hiwase, Devendra, Schreiber, Andreas W, Hahn, Christopher N, Scott, Hamish S, Liu, Paul P., and Godley, Lucy A.

Published
2022
Full Text
View/download PDF

42. A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome.

Author

DiNardo, Courtney D., Hochhaus, Andreas, Frattini, Mark G., Yee, Karen, Zander, Thomas, Krämer, Alwin, Chen, Xueying, Ji, Yan, Parikh, Nehal S., Choi, Joanne, and Wei, Andrew H.

Subjects
ACUTE myeloid leukemia, MYELODYSPLASTIC syndromes, ISOCITRATE dehydrogenase, AMINO acid residues, ASPARTATE aminotransferase, GLUCOSE-6-phosphate dehydrogenase deficiency, TUMOR lysis syndrome
Abstract

Purpose: Isocitrate dehydrogenase enzyme 1 (IDH1) mutations at 132nd amino acid residue (R132*) result in the cellular accumulation of the oncometabolite, 2-hydroxyglutarate (2-HG). IDH305 is an orally bioavailable, brain-penetrant, mutant-selective allosteric IDH1 inhibitor demonstrating target engagement in preclinical models. This first-in human study was designed to identify the recommended dose for expansion/maximum tolerated dose of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Methods: IDH305 was given at doses 75–750 mg twice daily in 41 patients with IDH1R132-mutant AML/MDS. Dose escalation was designed using Bayesian hierarchical model with overdose control principle and relationship with dose-limiting toxicity. Results: IDH305 exhibited rapid absorption with mean T1/2 approximately 4–10 h across doses. Interpatient variability was moderate and exposure increased with dose in a less than dose proportional manner. Most patients (35/41) demonstrated target engagement with reduction in 2-HG concentration at all doses. Complete remission (CR) or CR with incomplete count recovery occurred in 10/37 (27%) patients with AML and 1/ 4 patients with MDS. Adverse events (AEs) suspected to be related to study drug were reported in 53.7% of patients: increased blood bilirubin (14.6%), nausea (14.6%), increased alanine aminotransferase and aspartate aminotransferase (12.2%, each); most frequent grade 3 or 4 AEs were differentiation syndrome and tumor lysis syndrome (n = 3; 7.3%, each). Hepatotoxicity was manageable with dose modification. Conclusion: Due to potentially narrow therapeutic window, the study was prematurely halted and recommended phase 2 dose could not be declared. Trial registration: Clinicaltrials.gov identifier: NCT02381886. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma

Author

Hose, Dirk, Rème, Thierry, Meissner, Tobias, Moreaux, Jérôme, Seckinger, Anja, Lewis, Joe, Benes, Vladimir, Benner, Axel, Hundemer, Michael, Hielscher, Thomas, Shaughnessy, John D., Jr, Barlogie, Bart, Neben, Kai, Krämer, Alwin, Hillengass, Jens, Bertsch, Uta, Jauch, Anna, De Vos, John, Rossi, Jean-François, Möhler, Thomas, Blake, Jonathon, Zimmermann, Jürgen, Klein, Bernard, and Goldschmidt, Hartmut

Published
2009
Full Text
View/download PDF

49. Risk factors for cancers of unknown primary site: Results from the prospective EPIC cohort

Author

Kaaks, Rudolf, Sookthai, Disorn, Hemminki, Kari, Krämer, Alwin, Boeing, Heiner, Wirfält, Elisabet, Weiderpass, Elisabete, Overvad, Kim, Tjnneland, Anne, Olsen, Anja, Peeters, Petra H., Bueno-de-Mesquita, B(as) H., Panico, Salvatore, Pala, Valeria, Vineis, Paolo, Quirós, Ramón J., Ardanaz, Eva, Sánchez, María-José, Chirlaque, Maria-Dolores, Larrañaga, Nerea, Brennan, Paul, Trichopoulos, Dimitrios, Trichopoulou, Antonia, Lagiou, Pagona, Hallmans, Göran, Khaw, Kay-Tee, Key, Timothy J., Riboli, Elio, and Canzian, Federico

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results